8 Questions
Which of the following patients would qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
A patient with type 2 diabetes and an HbA1c of 52 mmol/mol, despite regular use of metformin for 3 months
Which of the following is NOT a criterion for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
Five-year CV risk < 15%
Why are ethnicity and age-group clauses included in the Special Authority criteria for funded SGLT2i and GLP1RA therapy?
To reduce barriers in high-risk populations
Which of the following patients should be offered the opportunity to self-fund empagliflozin and/or liraglutide or dulaglutide?
Patients who meet the Special Authority criteria for one agent and would benefit from dual SGLT2i/GLP1RA therapy
What is the reason for not allowing patients to be on funded empagliflozin and dulaglutide or liraglutide at the same time?
Financial constraints
What additional benefits can be expected from dual SGLT2i/GLP1RA therapy?
Additional reductions in glucose levels and weight
Which of the following patients would NOT qualify for funded SGLT2i and GLP1RA therapy according to the Special Authority criteria?
A patient with type 2 diabetes and an HbA1c of 50 mmol/mol, despite regular use of metformin for 3 months
What is the purpose of the Special Authority criteria?
To ensure only the most severe cases receive funded SGLT2i and GLP1RA therapy
Test your knowledge on the monitoring and management of HbA1c, eGFR, and blood pressure in patients. Learn about the use of GLP1RA in specific patient populations.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
